Ypsomed Holding AG (GB:0QLQ)
LSE:0QLQ
0QLQ Stock Chart & Stats
CHF312.00
-CHF0.50(-0.15%)
At close: 4:00 PM EST
CHF312.00
-CHF0.50(-0.15%)
Day’s Range― - ―
52-Week RangeCHF263.50 - CHF440.00
Previous CloseN/A
Volume11.46K
Average Volume (3M)3.13K
Market Cap
CHF3.84B
Enterprise ValueCHF3.92B
Total Cash (Recent Filing)CHF36.30M
Total Debt (Recent Filing)CHF110.00M
Price to Earnings (P/E)7.7
Beta0.44
Next Earnings
May 27, 2026Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)10.19
Shares Outstanding13,649,739
10 Day Avg. Volume2,034
30 Day Avg. Volume3,135
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)6.82
Price to Sales (P/S)6.19
P/FCF Ratio-35.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.27
Revenue Forecast (FY)CHF703.04M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth (36.5% year-over-year) indicates expanding commercial traction across Drug Delivery and Diabetes Care. Structurally, this growth signals strong partner adoption of device platforms and growing recurring product volumes, supporting scale benefits and longer-term contract visibility over the next 2–6 months.
Profitability & MarginsRobust gross and operating margins demonstrate durable operational efficiency in device manufacturing and services. High margins in Delivery Systems allow reinvestment in R&D and capacity while absorbing pricing pressure from partners, supporting sustainable earnings quality and cash generation potential over the medium term.
Balanced Capital Structure & ReturnA conservative leverage profile and healthy ROE provide financial flexibility to fund growth capex and capacity expansion. The balanced equity ratio reduces refinancing risk and supports strategic investments (capacity, sustainability platforms) without excessive debt strain, preserving resilience through multi-quarter execution cycles.
Bears Say
Negative Free Cash FlowPersistently negative free cash flow driven by heavy capex limits internal funding for growth and increases reliance on external financing or partner co-investment. Over a 2–6 month horizon, this pressures liquidity allocation and raises execution risk as the company scales production and invests in its 1.5 billion CHF growth program.
Diabetes Care Segment LossA loss in the Diabetes Care unit weakens a business expected to deliver recurring consumable revenues. Structural underperformance in this segment may require additional investment or restructuring, which can dilute margins and divert management focus during the next several quarters as the company seeks to scale profitable usage.
Contract Manufacturing PhaseoutPlanned phaseout of contract manufacturing creates a foreseeable and material revenue headwind, reducing utilization and near-term top-line predictability. Replacing this revenue depends on timely commercialization of partner projects and internal capacity uptake, increasing execution dependency over the medium term.
Ypsomed Holding AG News
0QLQ FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest share price was CHF263.50 and its highest was CHF440.00 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF3.84B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is May 27, 2026 which is in 48 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on Nov 12, 2025. The company reported CHF10.19 earnings per share for the quarter, beating the consensus estimate of CHF9.11 by CHF1.08.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Overvalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF2.2 which represents an annual dividend yield of 0.68%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 6.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF10.19 in its last earnings report, beating expectations of CHF9.11. Following the earnings report the stock price went up 5.508%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in GB:0QLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Technical Analysis
Options Prices
Currently, No data available
---